Trials / Completed
CompletedNCT05870956
Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
Economic Burden Associated With Nintedanib Non-adherence Among Medicare Beneficiaries With IPF
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,798 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 66 Years
- Healthy volunteers
- Not accepted
Summary
This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient hospitalization, among patients with Idiopathic Pulmonary Fibrosis (IPF). 2. To assess the association between a patient's nintedanib adherence trajectory group (as measured from a GBTM) and their medical costs among patients with IPF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | Nintedanib |
Timeline
- Start date
- 2023-05-16
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2023-05-23
- Last updated
- 2024-10-01
- Results posted
- 2024-10-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05870956. Inclusion in this directory is not an endorsement.